<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - CABOZANTINIB</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>CABOZANTINIB</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                140 mg once daily, for dose adjustment or treatment interruption due to side effects, consult product literature (closely monitor for first 8 weeks of therapy).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Cabozantinib is an inhibitor of several protein kinases.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid unless potential benefit outweighs risk&#8212;toxicity in <i>animal</i> studies.</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Manufacturer advises caution in renal impairment.</p><p>Avoid in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Reversible Posterior Leukoencephalopathy Syndrome</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, abnormal hair growth, abscess, acne, alopecia, anal fissure, anxiety, arthralgia, aspiration, atrial fibrillation, blurred vision, cheilitis, chills, cholelithiasis, constipation, decreased appetite, dehydration, depression, diarrhoea, dizziness, dry skin, dysgeusia, dyspepsia, dysphagia, dysphonia, dysuria, erythema, face oedema, folliculitis, fungal infection, gastro-intestinal perforation, gastrointestinal haemorrhage, glossodynia, haematuria, haemorrhoids, hair colour changes, headache, hyperbilirubinaemia, hyperkeratosis, hypertension, hypoalbuminaemia, hypocalcaemia, hypokalaemia, hypophosphataemia, hypotension, hypothyroidism, impaired wound healing, lymphopenia, mucosal inflammation, muscle spasms, musculoskeletal chest pain, nausea, neutropenia, non-gastro-intestinal fistula, oropharyngeal pain, osteonecrosis of jaw, pallor, palmar-plantar erythrodysaesthesia syndrome, pancreatitis, paraesthesia, peripheral coldness, peripheral neuropathy, platelet disorders, pneumonia, proteinuria, pulmonary embolism, rash, respiratory tract haemorrhage, skin exfolation, skin hypopigmentation, stomatitis, tinnitus, tremor, venous thrombosis, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> Hypoacusis, acute renal failure, amenorrhoea, angina, arterial thrombosis, aspergilloma, ataxia, atelectasis, cataract, conjunctivitis, cyst, delirium, facial pain, gastro-intestinal fistula, hepatic encephalopathy, loss of consciousness, oesophagitis, pharyngeal oedema, pneumonitis, posterior reversible encephalopathy syndrome, rhabdomyolysis, skin ulcer, speech disorder, supraventricular tachycardia, telangiectasia, transient ischaemic attack, vaginal haemorrhage,
              </p>
              <p>
                <strong>notKnown:</strong> Bone-marrow suppression, hyperuricaemia, oral mucositis, thromboembolism, tumour lysis syndrome,
              </p>
        
        
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Food should not be consumed for at least 2 hours before and at least 1 hour after each dose.</p>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>Risks of incorrect dosing of oral anti-cancer medicines</h3>
              <p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p><p>Standards to be followed to achieve this include:</p><ul>
            <li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>
            <li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>
            </ul>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Hypertension&#8212;discontinue treatment if uncontrolled despite medical intervention
          </li>
          <li>
            palmar-plantar erythrodysaesthesia syndrome&#8212;consider treatment interruption if severe and restart at a lower dose when resolved to grade 1
          </li>
          <li>
            patients at increased risk of fistulas&#8212;consult product literature
          </li>
          <li>
            patients at increased risk of gastro-intestinal perforation&#8212;consult product literature
          </li>
          <li>
            patients at increased risk of intra-abdominal abscess&#8212;consult product literature
          </li>
          <li>
            patients at risk of haemorrhage (including tumour involvement of the trachea or bronchi)&#8212;discontinue if symptoms develop
          </li>
          <li>
            patients at risk of thromboembolic events including myocardial infarction&#8212;discontinue if symptoms develop
          </li>
          <li>
            risk of osteonecrosis of the jaw
          </li>
          <li>
            susceptibility to QT-interval prolongation (e.g. cardiac disease, electrolyte disturbances, bradycardia, concomitant use of drugs that prolong the QT interval)&#8212;monitor ECG and electrolytes periodically
          </li>
        </ul>
        <ul>
          <li>
            <p>Withhold treatment for at least 28 days before elective surgery and restart only if adequate wound healing&#8212;discontinue in patients with wound healing complications requiring medical intervention.</p>
          </li>
          <li>
            <p>Discontinue treatment at least 28 days before elective invasive dental procedures&#8212;monitor for symptoms before and during treatment and discontinue if osteonecrosis develops.</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins&#8212;patients and their sexual partners must use effective contraception (in addition to barrier method) during treatment and for at least 4 months after the last dose.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor urine protein regularly and discontinue if nephrotic syndrome develops.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of CABOZANTINIB</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP101372"><a href="../medicinalForm/PHP101372.html" data-target="#PHP101372" data-action="load">Capsule</a></div>
            <div id="PHP0000153"><a href="../medicinalForm/PHP0000153.html" data-target="#PHP0000153" data-action="load">Not applicable</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
